Evidence map›Paper›PMID 41293202›Full record

ArticleFrontiers in psychiatry2025

Feasibility of the development and psychometric properties of a standardized screening instrument for mental disorders in patients with suspected rare diseases: results of the ZSE-DUO study.

Lilly Sophia Brandstetter, Kathrin Ungethüm, Peter U Heuschmann, Lisa Pfister, Jürgen Deckert, Martina de Zwaan, Oliver Tüscher, Stefanie Witt, Christian Krauth, Alexandra Berger and 9 more

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lilly Sophia BrandstetterInstitute for Clinical Epidemiology and Biometry, Julius-Maximilian University Würzburg, Würzburg, Germany.
Kathrin UngethümInstitute for Clinical Epidemiology and Biometry, Julius-Maximilian University Würzburg, Würzburg, Germany.
Peter U HeuschmannInstitute for Clinical Epidemiology and Biometry, Julius-Maximilian University Würzburg, Würzburg, Germany.
Lisa PfisterCentre for Rare Diseases, University Hospital Würzburg, Würzburg, Germany.
Jürgen DeckertInstitute for Clinical Epidemiology and Biometry, Julius-Maximilian University Würzburg, Würzburg, Germany.
Martina de ZwaanDepartment of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.
Oliver TüscherDepartment of Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany.
Stefanie WittCenter for Psychosocial Medicine, Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian KrauthCentre for Health Economics Research Hannover and Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.
Alexandra BergerFrankfurt Reference Centre for Rare Diseases, University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt, Germany.
Mark BerneburgCentre for Rare Diseases Regensburg, University Hospital Regensburg, Regensburg, Germany.
Anna DeibeleDepartment of Psychosomatic Medicine and Psychotherapy, University Hospital Magdeburg, Magdeburg, Germany.
Jan Dieris-HircheDepartment of Psychosomatic Medicine and Psychotherapy, LWL-University Hospital, Ruhr University Bochum, Bochum, Germany.
Gereon HeuftDepartment of Psychosomatic Medicine Und Psychotherapy, University Hospital Münster, Münster, Germany.
Christiane ImhofDepartment of Psychosomatic Medicine and Psychotherapy, Ulm University Medical Center, Ulm, Germany.
Jörg Bernhard SchulzDepartment of Neurology, RWTH Aachen University, Aachen, Germany.
Stephan ZipfelDepartment of Psychosomatic Medicine and Psychotherapy, University of Tübingen, Tübingen, Germany.
Helge HebestreitCentre for Rare Diseases, University Hospital Würzburg, Würzburg, Germany.
Kirsten HaasInstitute for Clinical Epidemiology and Biometry, Julius-Maximilian University Würzburg, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients presenting in centers for rare diseases (CRDs) show complex symptoms, requiring multiprofessional expertise. Many patients suffer from unnoticed mental disorders. Currently, mental health experts (MHEs) are rarely involved in the diagnostic process. The aim of this study was to test the feasibility of developing a new short screening instrument for mental disorders and to test its predictive value. Methods: Data were derived from 1,300 adult patients participating in ZSE-DUO (dual guidance structure in centers for rare diseases), a multicenter study in 11 CRDs (funded by G-BA, Grant 01NVF17031), evaluating the benefit of involving an MHE in the diagnostic process. Patients completed standardized questionnaires on anxiety [the 7-item Generalized Anxiety Disorder (GAD-7)], depression [the 9-item Patient Health Questionnaire (PHQ-9)], dissociation [4-item Dissociation-Tension Scale (DSS-4)], psychopathology [Symptom-Checklist K-9 (SCL-K-9)], and quality of life [12-item Short Form Health Survey (SF-12) and EQ-5D-5L] prior to and during their first CRD visit as part of the routine assessment necessary for a first contact at a CRD. Exploratory factor analysis (EFA) was performed for item reduction. The reliability of the factor structure was assessed using Cronbach's α. Model fit was tested using confirmatory factor analysis (CFA). The predictive value of the new screening instrument was tested by calculating a receiver operating characteristic (ROC) curve using the diagnoses from the MHE. Results: The extracted 18-item model had a four-factor structure with acceptable to high reliability. The extracted mental health dimensions were 1) anxiety and depression, 2) mobility and activities of daily living, 3) energy or fatigue, and 4) dissociation. Excluding the dimension "dissociation" (well assessed using the DSS-4 separately), a summary score was calculated ranging from 0 to 45, with the lowest score representing the best mental health. In the CFA, the model fit indices for the extracted factor structure did meet the established thresholds. The predictive value of the new screening instrument on any mental disorder was moderate [area under the curve (AUC)=0.68; 95% CI=0.64-0.73]. Conclusion: The design of a new short screening instrument for mental disorders in patients presenting at CRDs was feasible. Furthermore, the new short screening instrument may help MHEs to identify patients in need of a more thorough screening and adapted care, particularly in identifying patients with potential depressive disorders. However, due to the heterogeneity of the mental disorders in this patient group, in addition, individual assessment of patients by MHEs is necessary.

Indexed as

confirmatory factor analysismental healthquestionnaire developmentrare diseasesscreening instrument

Identifiers

PMID41293202
PMCPMC12641394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.